DYNC1I1: A Drug Target / Disease Biomarker (G1780)

Target Name: DYNC1I1

NCBI ID: G1780

DYNC1I1

DYNC1I1: A Drug Target / Disease Biomarker

DYNC1I1, also known as CSF1, is a protein that is expressed in the cerebellum, which is the part of the brain responsible for motor coordination and balance. It is a key regulator of the development and maintenance of motor neurons, which are responsible for transmitting signals from the brain to the muscles to control movement.

Recent studies have identified DYNC1I1 as a potential drug target for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Its role in these conditions has been attributed to its involvement in the regulation of neurotransmitter signaling, as well as its role in the development and maintenance of synaptic plasticity, which is the ability of the brain to change and adapt over time.

One of the key functions of DYNC1I1 is its role in the regulation of dopamine signaling. Dopamine is a neurotransmitter that is involved in motor control and mood regulation, and its levels are often affected in conditions such as Alzheimer's disease and Parkinson's disease. Studies have shown that DYNC1I1 plays a role in regulating the levels of dopamine in the brain, and that its dysfunction may contribute to the development of these conditions.

In addition to its role in dopamine signaling, DYNC1I1 is also involved in the regulation of other neurotransmitters, including GABA, which is a neurotransmitter that is involved in anxiety and depression. Studies have shown that DYNC1I1 plays a role in regulating the levels of GABA in the brain, and that its dysfunction may contribute to the development of these conditions.

DYNC1I1 is also involved in the regulation of cytoskeletal dynamics, which is the movement of cells within the body. This is important for the proper functioning of many tissues and organs, including muscles and neurons. Studies have shown that DYNC1I1 plays a role in regulating the cytoskeletal dynamics of motor neurons, and that its dysfunction may contribute to the development of certain neurological conditions.

In conclusion, DYNC1I1 is a protein that is expressed in the cerebellum and is involved in the regulation of various neurotransmitter signaling pathways that are important for the development and maintenance of motor neurons. Its dysfunction has been linked to the development of a number of neurological and psychiatric conditions, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Therefore, DYNC1I1 is a potential drug target for these conditions, as well as for other neurological and psychiatric disorders.

Protein Name: Dynein Cytoplasmic 1 Intermediate Chain 1

Functions: Acts as one of several non-catalytic accessory components of the cytoplasmic dynein 1 complex that are thought to be involved in linking dynein to cargos and to adapter proteins that regulate dynein function. Cytoplasmic dynein 1 acts as a motor for the intracellular retrograde motility of vesicles and organelles along microtubules. The intermediate chains mediate the binding of dynein to dynactin via its 150 kDa component (p150-glued) DCTN1. May play a role in mediating the interaction of cytoplasmic dynein with membranous organelles and kinetochores

The "DYNC1I1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DYNC1I1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets